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ReviewAutoimmunity and Apoptosis:
The Crohn’s Connection
A Positional Triumph, Occasioning New Questions
Though mostly sporadic, Crohn’s disease is sometimes
familial, a fact used to advantage in the assignment
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10550 North Torrey Pines Road of susceptibility loci. The strongest genetic association
with Crohn’s involves a chromosome 16 locus, desig-La Jolla, California 92037
nated IBD1 (Curran et al., 1998). Loci on chromosomes
1p, 3q, 4q, and 12q have also been described (Cho et
The Fundamental Question: Autoimmune al., 1998; Curran et al., 1998). In a recent issue of Nature,
Hugot et al. (2001) and Ogura et al. (2001a) have reportedversus Infectious
A protean malady of unknown cause, Crohn’s disease that mutations of the gene encoding NOD2 are strongly
associated—and almost certainly etiologically linked—classically occurs as a relapsing/remitting “regional ile-
itis” but can affect any part of the gastrointestinal tract, to the development of Crohn’s disease. While not all
Crohn’s disease can be explained by the NOD2 muta-not merely the terminal ileum. On rare occasions, lesions
are observed even in the oropharynx or esophagus. His- tions found so far, the bulk of the chromosome 16 asso-
ciation with Crohn’s disease is explained by the findings.tologically, the lesions are intensely inflammatory, and
they may lead to the formation of fistulae between en- In fact, pooling all variant alleles from the study of Hugot
et al., it would appear that 201/468 patients and onlyteric (and sometimes nonenteric) structures. Crohn’s
disease and ulcerative colitis are the two major forms 15/103 controls displayed coding changes, a figure that
is overwhelmingly significant in itself and takes no ac-of inflammatory bowel disease (IBD). Crohn’s disease
can be distinguished from ulcerative colitis on both clini- count of deep intronic mutations, promoter mutations,
large deletions, and the like. We shall come to the func-cal and histopathologic grounds. Ulcerative colitis is
not associated with fistulae, it affects only the colon, tion of NOD2 presently. But first, let us consider pre-
cisely what was done.producing characteristic shallow, ulcerative lesions, and
it rather frequently presages the development of adeno- Hugot et al. used an unbiased genetic search based
first on linkage disequilibrium mapping, then on pedi-carcinoma of the colon (whereas Crohn’s disease does
not). The two diseases can also be distinguished on gree disequilibrium testing, and finally on very extensive
sequence analysis of the best candidate gene. This isthe basis of their responses to therapy: TNF blockade
usually yields an excellent response in Crohn’s disease to say that they built their case in a rigorous and pain-
staking manner. They ultimately identified a multitude(Van Dullemen et al., 1995) but rarely or never does so
in ulcerative colitis. of mutations (more than 30 in all), the great majority of
which were observed only in Crohn’s patients. This is aCrohn’s disease has widely been considered an auto-
immune disorder, although an infectious cause cannot key point in the establishment of a causal relationship,
since an isolated mutation might be dismissed as abe excluded. Recurrent hypotheses have held that mi-
crobial flora contribute initiators that trigger the disease, nonetiologic marker in linkage disequilibrium with the
authentic defect.or, in some cases, prevent disease. Several knockout
mutations produce IBD, and, in at least one case (the Ogura et al. appear to have proceeded in a more
intuitive fashion, declaring NOD2 as a candidate locusTCR knockout mouse), germ-free animals fail to de-
velop colitis, suggesting the pathogenic involvement of from the very outset. They identified three mutations in
NOD2, one of which was the relatively common distallymicrobial flora (Bhan et al., 2000). A caprine mycobacte-
rial model of Crohn’s disease has been presented as placed frameshift error also found by Hugot et al.
The clear causality of the NOD2 mutations in familialevidence of an infectious cause (Van Kruiningen et al.,
1986). But in the authentic human disease, no microbial Crohn’s disease illustrates the resolving power of pure
genetic methods, applied to a complex disease in thepathogen (and indeed, no commensal) has ever been
shown to play an essential role. Perhaps the best evi- postgenomic era. Not only is the solidity of the core
dence of involvement of microbes is the therapeutic discovery beyond question, but it is doubtful that the
effect of antibiotics in Crohn’s disease: changing the discovery could have been made in the absence of geno-
microbial flora does appear to alter clinical course. But mic data—at least any time soon. A point not much
this observation is difficult to interpret. First, as already emphasized in either study, but nonetheless true, is the
noted, the disease may occur in any part of the gastroin- inference that some cases of Crohn’s disease are proba-
testinal tract, and bacterial flora differ widely from one bly solely attributable to NOD2 mutations. It is not the
end to the other. Moreover, a primary inflammatory pro- case, as might earlier have been thought, that a chance
cess might permit the entry of microbes and microbial association of a large collection of susceptibility alleles
products into the submucosa or lamina propria, leading at different loci are required for disease to develop.
to an amplification loop in which inflammation is aug- Rather, at least in the case of the rare (private) mutations
mented and more mucosal damage occurs. Antibiotics that were observed by Hugot et al., an overwhelming
might mitigate this process. At any rate, there is no correlation is observed with disease, as much so as with
concrete proof of a microbial “first cause.” a monogenic disorder of rather high penetrance. This
speaks to the type of variants responsible for polygenic
disease in general. For at least some diseases, isolated1Correspondence: bruce@scripps.edu
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rare mutations at several unlinked (but perhaps function- Likewise, the comment of Ogura et al. that “genetic
variation in the LRRs of TLR4 accounts for inter-individ-ally related) loci can have determinative importance.
Inevitably, victory over such a difficult and important ual differences in bronchial responsiveness to aerosol-
ized LPS” is unfounded. The truth is that the mutationsproblem yields a sense of elation. The work of Hugot et
al. and Ogura et al. have placed the notion that Crohn’s cited—whatever their phenotypic effect—do not reside
within the LRRs but between them (at residues 299 anddisease has a discrete genetic etiology on firmer footing
than ever before. Yet, where interpretation is concerned, 399 of the polypeptide chain). Ogura and colleagues
actually make some fairly hazardous turns, both in theirthe matter remains perplexing. In neither report do the
authors draw mechanistic interpretations that lie beyond experiments and in their conclusions. Transfecting
HEK293 cells with NOD2 expression plasmids and thenthe realm of honest debate. As to the question of first
cause, the debate has been sharpened rather than exposing the cells to exceedingly high concentrations
of LPS (10 g/ml), these authors maintain that NOD2settled.
creates sensitivity to LPS and offer that it does so by
acting as an “intracellular receptor” for LPS. In the caseThe NOD Proteins in Relief
of NOD1, the authors have earlier pointed to other evi-NOD2 (and its closest homolog NOD1) are remarkable
dence in support of an intracellular LPS receptor (Ino-proteins in that they each contain N-terminal caspase
hara et al., 2001) and have explained that some cells,recruitment domain (CARD) motifs, a single, more cen-
such as those of the intestinal mucosa, would be ill-trally placed nucleotide (ATP or GTP) binding motif, and
served by responding to LPS in the external milieu. Truestill more distally placed leucine-rich repeats (LRRs; all
enough. But extremely strong evidence would be re-of them of the ribonuclease inhibitor type) (Figure 1).
quired to sustain the hypothesis of a cytoplasmic sensorMore distant relatives bearing at least partially similar
for LPS, and, so far, only a few publications may bedomain structure include CLAN (a.k.a. CARD12 or IPAF
brought to bear on the matter.[Poyet et al., 2001; Geddes et al., 2001]) and Apaf-1.
CARD motifs are functionally and structurally related
to death domains (DDs) and are famously (though not Microbial Sensors within the Cell?
For several decades, LPS has been taken as the quintes-universally) involved in pathways leading to programmed
cell death. Their function is discussed in detail below. sential microbial activator of innate immune responses.
Genetic studies of LPS sensing led directly to the pres-Nucleotide binding motifs exist in many proteins of di-
verse function. In the proteins under discussion here, ent concept that TLRs are the principal sensors of the
innate immune system (Poltorak et al., 1998a, 1998b).they are believed to comprise a “self-oligomerization”
motif. LRRs, which are also very common and exist in What is true for LPS may not be true for all microbial
molecules. Some may have intracellular sensors andproteins of diverse function, are here regarded as “li-
gand binding” or “activation” motifs. LRRs are, in the others may not. But for the present, since it has been
proposed that the NOD1 and NOD2 molecules may actminds of some, linked to the Toll-like receptor (TLR)
family. Both Hugot et al. and Ogura et al. have empha- as intracellular LPS sensors, we will confine our discus-
sion to LPS.sized the possibility of a functional connection between
the LRRs in the NOD2 protein and those in the TLRs, A substantial body of evidence now holds that there
is only one conduit for LPS signal transduction in mam-which are widely regarded as the primary sensors of
the innate immune system (Beutler, 2000; Aderem and malian cells, at least when LPS is presented from a
source external to the cell. This evidence does not pre-Ulevitch, 2000). It is here that a few errors of fact have
been made, and corrections are in order. clude the existence of multiple LPS concentrating mech-
anisms, nor does it cast doubt on the highly ramifiedWhen Hugot et al. comment that “susceptibility to
spontaneous inflammatory bowel disease (IBD) in mice character of the LPS signaling pathway. It may also be
the case that LPS is engulfed within a phagosome priorhas been associated with mutations in Toll-like receptor
4 (TLR4)—a member of a family of NF-B activators that to activation of the primary sensor. However, leaving
aside whatever happens above the membrane andis known to bind LPS through its LRR domains [authors’
references 19 and 20],” they are, in the main argument, whatever happens beneath, it has been understood for
over 30 years that in the absence of a single, criticalincorrect. So far as anyone knows, the Tlr4 mutation in
C3H/HeJ mice (corresponding to the P712H mutation) protein (formerly known as the product of the Lps locus
and now identified as TLR4 [Poltorak et al., 1998a]),has nothing at all to do with the colitis observed by
Sundberg et al. C3H/HeJ mice do not develop spontane- nothing much happens when LPS—externally pre-
sented—comes in contact with mammalian cells (Hepp-ous colitis, nor do C57BL/10ScCr mice, nor any other
mice with defects or deletions of the Tlr4 locus. Rather, ner and Weiss, 1965; Sultzer, 1968; Coutinho and Meo,
1978). Hence, so far as is known, cells derived fromthe C3H/HeJ-Bir substrain appears to have acquired
other mutations that cause colitis, unmapped (and es- C3H/HeJ and C57BL/10ScCr mice are indifferent to LPS
present in the surrounding the medium. LPS is knownsentially unstudied) to the present day (Sundberg et al.,
1994). No dependence upon a TLR4 mutation has been to be internalized by cells if presented to them in aggre-
gated form (Weel et al., 1989; Warner et al., 1985; Kriegs-established. Hugot et al. are correct in their observation
that TLR4 binds LPS in order to trigger cell activation mann et al., 1993), and at least some of it reaches the
cytosol (Diaz-Laviada et al., 1991; Municio et al., 1990).(Poltorak et al., 2000; da Silva et al., 2001). However,
the role of the LRR domains in binding is not yet estab- Nonetheless, TLR4 mutations forbid responses to LPS.
This would suggest that any “internal receptor” for LPSlished. It is entirely conceivable that LPS never has phys-
ical contact with the LRRs at all. would require a very exclusive route of presentation.
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Figure 1. The Structure of NOD Proteins versus TLRs
A common scale of size (amino acid length) applies to all three proteins. On the left, the structure of TLR4, the mammalian LPS receptor, is
deciphered using the SMART algorithm (Simple Modular Architecture Research Tool; http://smart.embl-heidelberg.de/). Green boxes depict
ectodomain LRRs, the blue oval depicts a cysteine-rich membrane-proximal LRR characteristic of most of the TLRs, the blue bar indicates
the transmembrane domain, and the green octagon represents the cytoplasmic TIR domain. The NOD1 and NOD2 proteins (right) bear a more
orderly array of LRRs, placed at the C-terminal end of the molecule and strongly reminiscent of the RI array of LRRs. Each NOD has a centrally
placed nucleotide binding domain (green circle) and either one or two N-terminal CARD motifs (pink octagons). The TLRs cannot be modeled
upon the three-dimensional structure of other proteins. However, using the CPH model server (http://www.cbs.dtu.dk/services/CPHmodels/),
it is possible to infer the  carbon trace of the NOD LRR clusters (lower middle), based on the crystal structure of RI (lower right). The NOD
LRR array is predicted to be remarkably similar to that of RI. In the figure, it has been “tilted” to lie within a different plane than the RI array
in order to better show the  helices that are formed by each of the LRR motifs.
Sansonetti and his colleagues (Philpott et al., 2000) LPS one of many molecules that fulfill the necessary
structural rules)? Does access of Gram-negative bacte-have used microinjection to introduce LPS directly into
the cytosol of epithelial cells and have demonstrated ria to the cytosol occur in a viable cell, and if so, does
it assure the presence of free LPS in the cytosol? More-the occurrence of NF-B activation under these condi-
tions. As their reasoning goes, many epithelial cells that over, the identity of the receptor is not addressed by
these studies.fail to respond to LPS (like those in the gut) nonetheless
require a means of detecting intracellular bacteria Ogura et al. now propose that NOD1 and NOD2 may
represent sensing molecules for LPS—perhaps thoseshould they gain entry to the cytosol. Although their
studies were performed using HeLa cells, which might detected by Philpott et al. A certain lapse of logic is
evident in that NOD2 expression is purportedly macro-well express an TLR4, the cells nonetheless fail to re-
spond to LPS presented externally by activating NF-B, phage specific, and macrophages (unlike epithelial cells)
are certainly capable of sensing LPS in their externaland, therefore, some form of detection must occur when
microinjection of LPS is performed. environment. They are not (like epithelial cells) com-
pelled to live in contact with enormous concentrationsThe data are interesting but leave certain questions
unanswered. It is difficult to say just what class of mole- of LPS. But leaving such arguments aside, the case
for assigning a sensing function to NOD1 and/or NOD2cules is sensed. Is the detection unique to LPS, or are
a wide variety of microbial molecules capable of trig- remains weak.
Unfortunately, the authors have chosen an inadequategering a response through the same pathway (i.e., is
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means to test the LPS sensing function of the candi- has LRR motifs. In this characteristic, it shares a struc-
tural motif with TLR4, which indisputably does bind LPSdates. The approach is essentially the same as that used
by their forebears in the TLR field, who once regarded (Poltorak et al., 2000; Lien et al., 2000; da Silva et al.,
2001). However, it must be observed that the denselyTLR2 as the LPS receptor (Yang et al., 1998; Kirschning
et al., 1998), an idea now all but universally rejected. packed LRR array present in each of the NOD proteins
differs markedly from the haphazard array of LRRs inThe notion of TLR2-based LPS signaling was derived
from the response that was elicited when HEK293 cells the TLR ectodomains, which are often widely separated
from one another by zones of indeterminate structurewere transfected to express TLR2 at high copy number
and then exposed to high concentrations of LPS. Never (Figure 1). The LRRs in TLR protein ectodomains (the
“typical” type) are structurally distinguishable fromconsistent with the view that there must be a single
sensing pathway for LPS—at least when it is presented those in defensive proteins of plants and from those in
the NODs (the “Ribonuclease Inhibitor” type). In addi-from the outside of the cell—the phenomenon was ulti-
mately ascribed to contaminants present in commercial tion, the distribution of the LRRs within the NOD proteins
is strongly suggestive of the LRR array in ribonucleaseLPS preparations (Hirschfeld et al., 2000). There is no
reason to think otherwise in the present case. Just as inhibitor (RI), the 3D structure of which has been solved
at a high resolution (Kobe and Deisenhofer, 1993). In-LPS was shown to bind to NOD1 (Inohara et al., 2001),
Yang and colleagues showed that LPS could bind to deed, simple modeling exercises show that, like the RI
array, the NOD1 arrays yield a “horseshoe” shape, albeitTLR2. But in neither case was binding shown to be of
high affinity or specificity. a partial one. A first guess as to the function of such a
motif array would be that, like RI (which tightly associ-The overall lesson is clear: when analyzing the LPS
response pathway, hard genetic data (i.e., natural or ates with RNase A according to crystallographically de-
fined interactions [Kobe and Deisenhofer, 1995]), thetargeted mutations) should be coupled with the use of
a highly purified (or better still, chemically synthesized) NODs engage yet-unidentified protein ligands rather
than LPS.agonist. So far, there is no “strong” evidence to support
a direct role for NOD1 or NOD2 in LPS sensing, notwith- Ogura and colleagues suggest that the NOD1 and
NOD2 proteins are homologs of defensive proteins instanding the transfection-based studies that the authors
have presented. Strong evidence of the thesis that NOD plants that contain nucleotide binding domains and
LRRs. The assertion is a tenuous one. The case forproteins act as cytoplasmic receptors would entail (1)
a well-controlled demonstration that chemically synthe- homology between plant and animal proteins that bear
TIR motifs is quite secure because TIRs are rare motifs,sized LPS is sensed when injected into the cytoplasm
of cells from mice lacking TLR4 and (2) demonstration very large compared with LRRs, and, across vast evolu-
tionary distances, they exhibit a defensive function. Butthat mice lacking NOD proteins cannot respond to the
same stimulus. given the relative abundance and functional diversity of
nucleotide binding domains and LRRs in mammalianOf course, one cannot ignore the possibility that the
NOD proteins contribute to LPS signaling at some point proteins, a claim of common descent is much harder to
downstream from the receptor (and there is no funda- support. Ogura et al. also point to the similarity between
mental argument against such a possibility). But so far, Apaf-1/Ced4/Dark and the two NOD proteins. Here, a
no compelling data have been presented in support of case for common ancestry is even harder to support.
this scenario either. Apaf-1 has no LRRs at all, only a CARD domain and
Another question of interpretation is immediately WD40 motifs. The LRR and WD40 motifs are rarely found
raised. If the NOD proteins do not initiate signals in within the same protein, and they certainly did not arise
response to stimulation by an external agent (i.e., LPS), from a common ancestral sequence during eukaryotic
they most likely act as signaling intermediates. Inohara evolution, both motifs being found in diverse plant and
et al. (1999) and Ogura et al. (2001a, 2001b) have shown animal representatives.
that NOD1 and NOD2 can activate NF-B via RIP2, which However, a case for common function (that is, conver-
establishes a physical connection between the two mol- gent evolution) can be made. The WD40 motifs and LRRs
ecules. However, the “direction” of signaling is less might both subserve activation. The former is believed to
clear. The fact that RIP2 is able to initiate NF-B translo- form a “propeller” assembly, while the latter forms a
cation when engaged by NOD2 says nothing of the origin “horseshoe.” The WD40 motifs repress activation of the
of the signal. NOD2 might be activated to engage RIP2, protein in the absence of cytochrome C. However, akin
or RIP2 might be activated to engage NOD2. The issue to receptors that function as molecular “switches,” cyto-
is discussed further below, but, to begin with, some chrome C modifies the conformation of the WD40 array
phylogenetic perspective might be of use, since the and permits self-oligomerization to occur via the nucleo-
relative position to which the NOD proteins have been tide binding domain. This permits transproteolytic acti-
assigned in the signaling pathway has been based partly vation of caspase-9 as a result of induced proximity.
upon inferred relationship to other proteins, and the Caspase-9, which is attached to Apaf-1 through a CARD
credibility of these inferences is therefore an important interaction, then causes more distal events in the apo-
issue. ptotic cascade (Li et al., 1997; Zou et al., 1997). Densely
packed LRR motifs are known in at least one instance
to have a protein binding function as well (Kobe andThe Ancestry of Apaf-1, the NOD Proteins,
and Defensive Plant Proteins: Convergent Deisenhofer, 1995). So it might be granted that the NODs
are similarly paired with a target caspase via CARD(Rather Than Divergent) Evolution
At least in part, the hypothesis that LPS directly binds interaction, activated by binding a specific molecular
target and subject to self-oligomerization as well.to NOD2 seems to have grown from the fact that NOD2
Review
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In general, CARDs (like the leucine zipper motifs or that systemic inhibition of TNF activity can create a
lupus-like syndrome. In fact, about 1% of patients un-TIR motifs of some defensive plant proteins) have the
role of assuring targeted bimolecular pairing. And NBDs dergoing TNF blockade through treatment with antibod-
ies or soluble receptor develop reversible systemic lu-are believed to cause oligomerization, fostering autocat-
alytic activation of caspases. Hence, these proteins do pus erythematosus, and nearly 10% develop anti-DNA
antibodies (Charles et al., 2000; Schaible, 2000), whichnot, for the most part, share a common descent but
have evolved to fulfill similar functions through the use may be taken as a partial phenotype.
A concordant observation is made when TNF is ad-of different molecular “tools.”
Ogura and colleagues believe that the NOD2 muta- ministered to mature mice of the NOD strain (“non-obese
diabetic”; no relation the proteins under discussiontions may be “gain-of-function” errors that augment mi-
crobial signaling. Most commonly, frameshift errors are here), which are prone to the development of autoim-
mune diabetes. Specifically, repeated low-dose expo-hypomorphs. But not always, and, in particular, the mu-
tation that has been found is very distally placed in the sure to TNF delays or prevents the development of the
disease (Jacob et al., 1990).coding region so that a nearly intact product is antici-
pated. Hugot et al. seem to be in harmony with the gain- Other inflammatory diseases also entail mutations of
genes encoding documented or assumed participantsof-function hypothesis. They argue that the mutations
might increase NF-B translocation and so elicit sponta- in cell death pathways. For example, familial Mediterra-
nean fever is linked to mutations in pyrin (the prototypeneous inflammation, as observed in Crohn’s disease.
Further, the notion of gain-of-function mutations is con- for the pyrin motif) (The International FMF Consortium,
1997), and autoimmune lymphoproliferative syndromesonant with the example of Apaf-1, wherein deletion of
the WD40 motifs can activate the protein, making it (ALPS) is most commonly caused by mutations in the
death domain of Fas but sometimes by mutations incytochrome C independent.
This interpretation may be correct, but some other caspase-10 (Wang et al., 1999). In all, at least eight
autoimmune/inflammatory disorders have now beenpossibilities remain to be examined as well.
linked to mutations encoding components of apoptotic
machinery (Table 1).Is It in the LRRs? Or Is It in the CARDs?
In each of the examples just presented, autoimmunityIn 1992, the lupus-like disease known to afflict mice
is favored by impairment of a death pathway, while auto-homozygous for the Lpr (lymphoproliferation) mutation
immunity is suppressed by exaggerated signalingwas ascribed to a rearrangement in the gene encoding
through a death pathway. To be sure, there are alsothe Fas antigen, a death-domain protein with homology
examples of an effect contrary to the one just mentioned.to the TNF receptor (Watanabe-Fukunaga et al., 1992;
TNF blockade, imposed in neonatal NOD mice and main-Adachi et al., 1993). A mutation within the Gld locus,
tained for a critical interval of time, can prevent thelong known to present a good phenocopy of Lpr (Roths
development of type I diabetes (Yang et al., 1994) andet al., 1984), was then found to specify a missense error
can also prevent the adoptive transfer of the disease toin a protein agreed to be the Fas ligand (Takahashi
successive generations of NOD-scid mice (Brown et al.,et al., 1994). The lymphoproliferative disease in Fas-
1998). TNF blockade is a highly effective means of treat-deficient mice is greatly accelerated in the presence of
ing most cases of Crohn’s disease and rheumatoid ar-a type I TNF receptor knockout mutation (Zhou et al.,
thritis. It has very much altered the clinical course of1996). These discoveries heralded recognition of the
both diseases.importance of death domains in the regulation of im-
The message is a strong one, if still confusing: pertur-mune function, for it seemed that without input through
bation of cell death pathways can alternately cause au-Fas, a well-characterized and highly penetrant form of
toimmune diseases or at least partially relieve them.autoimmunity would develop, and the phenotype was
In this regard, the tie between TNF blockade (whichworsened without input through closely related type I
ameliorates Crohn’s disease) and NOD2 mutationsTNF receptor. By now, other genes are known to modu-
(which appear causally related to the disease) raises anlate the Fas-deficient autoimmune phenotype, and al-
immediate flag. TNF has an indisputable death pathwaythough none has been positively identified, TLR4—
connection. NOD2 might potentially be tied to caspasewhich also has a death pathway connection (see
activation. Perhaps the two proteins even lie within abelow)—is an excellent candidate on the grounds of
common apoptotic pathway. The nature of the NOD2meiotic mapping studies (Wang et al., 1997), performed
mutations found to date has not been established. Oneprior to the discovery of identity between Lps and Tlr4.
reasonable hypothesis would hold that the mutationsAs noted by Wang et al., the Lps locus is linked to Lprm1,
act to amplify signals that emanate at the level of thea modifier of Fas-induced autoimmune vasculitis (the
TNF receptor. And this might plausibly explain the thera-Lpsd allele, which specifies a mutant TLR4 protein inca-
peutic effect of TNF blockade in Crohn’s disease—pable of transducing the LPS signal, has an inhibitory
something which has long been quite mysterious.effect on the development of the phenotype). In fact,
Lps is even more tightly linked than they realized, resid-
ing only about 200 kb away from D4MIT132, which was NOD2 and Its Place in the Apoptotic Cascade
The entanglement of inflammatory and apoptotic path-the marker most closely associated with Lprm1. And
there are no other candidate genes in the immediate ways has become familiar to workers in both fields dur-
ing the past several years, with the recognition thatvicinity.
The perceived importance of cell death pathways in cytokines such as TNF simultaneously activate cas-
pases and NF-B. The former induce apoptosis, whileautoimmunity has been strengthened by the observation
Immunity
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Table 1. Genes and Proteins Implicated in Autoimmunity and Cell Death
Gene or Protein Relevant Diseases Evidence
TNF Crohn’s disease; rheumatoid arthritis (RA); Blockade ameliorates Crohn’s disease and RA;
systemic lupus erythematosus (SLE) also causes SLE-like disease
TNF RI SLE Knockout accelerates autoimmune disease in mice
lacking Fas antigen
Fas ligand SLE Mutations create lymphoproliferation and SLE-like
disease
Fas antigen SLE; autoimmune lymphoproliferative Mutations create lymphoproliferation and SLE-like
syndrome (ALPS) disease; Death domain mutations related to ALPS
TLR4 (presumed acting SLE Lpsd allele genetically linked to modulation of SLE-like
by way of MyD88) vasculitis in mice lacking Fas antigen
Pyrin FMF Pyrin mutations cause recurrent serositis and fever
Caspase-10 ALPS Mutations associated with ALPS
NOD2 Crohn’s disease Mutations associated with Crohn’s disease
the latter suppresses apoptosis and promotes proin- more recently referred to as the PAAD [Bertin and DiStef-
ano, 2000; Pawlowski et al., 2001]). Although somewhatflammatory gene expression. The NOD2 mutational data
should be seen in this context. similar in overall fold (DD, DED, and CARD are each six-
helix bundles, and PD is predicted to be a six-helixAt least four types of protein interaction motif are
known to be involved in signal transduction leading to bundle), there is no example of heterotypic interaction
(i.e., DDs associate only with DDs, CARDs with CARDs,apoptosis via the caspases. These include the death
domain (DD), caspase recruitment domain (CARD), etc.). In the logic of cell death pathways, a CARD-bearing
protein ought to engage a CARD-bearing protein in adeath effector domain (DED), and pyrin domain (PD;
Figure 2. Pathways Engaging the NODs in the Apoptotic Cascade
Solid arrows indicate experimentally verified interactions; hypothetical interactions are indicated by broken arrows. The bidirectional arrow
indicates that the direction of signal propagation is unknown. The bimolecular interaction domains CARD, DED, and DD are shown in red
wherever they are known to occur. Proteins for which mutational or other strong data support an autoimmune association are shown in blue.
A link (highlighted in green) between the type I TNF receptor and RIP2 is described in the text. RIP2 undergoes a CARD interaction with NOD1
and, by implication, with NOD2. The latter may activate caspase-9. Caspase-1 may be activated directly by RIP2, although the binding of a




Figure 3. The General Effect of Apoptotic Blockade and Its Place in Autoimmune Disease
Failure of apoptosis, caused by mutation or inhibition of pathways at any level, leads to the enhancement of feedback signals that favor
apoptosis. Some proapoptotic mediators (including TNF and other proteins) also have strong proinflammatory effects. They may cause tissue
injury and also initiate and sustain an adaptive immune response. In the specific instance of Crohn’s disease depicted here, it may be offered
that the fundamental lesion is in the NOD2 protein. Overproduction of TNF is a homeostatic response to this lesion but ultimately contributes
to disease. Hence, TNF blockade is ameliorative in Crohn’s disease. A similar problem may exist in rheumatoid arthritis.
homodimeric or heterodimeric interaction, for the CARD, While RIP has a DD, RIP2 has a CARD, and RIP3
has no death-related interaction domain at all. RIP2 isDD, PD, and DED motifs have no known functions other
than an interactive one. believed to be recruited to the type I TNF receptor com-
plex via interactions with TRAFs 1, 5, and 6, as well asSome of the proteins bearing these interaction motifs
(e.g., RAIDD [Duan and Dixit, 1997], FADD [Chinnaiyan cIAP1 (McCarthy et al., 1998), and RIP3 has been shown
to undergo interaction with RIP (Sun et al., 1999). RIP2et al., 1995; Boldin et al., 1995], and ASC [Masumoto et
al., 1999] a.k.a. PYCARD [Martinon et al., 2001]) are can directly activate caspase-1, -2, and -9 (Sun et al.,
1999; Thome et al., 1998), a process known to be inhib-bifunctional, exhibiting two types of domain (DD and
CARD for RAIDD, DD and DED for FADD, PD and CARD ited in the case of caspase-1 by ICEBERG, a protein
that associates with the caspase target, preventing itsfor ASC). As such, they might potentially act as “connec-
tors” between different constituents of the apoptotic activation (Humke et al., 2000). RIP2 is also is known to
associate via its CARD with NOD1 (Inohara et al., 1999).“chain.” Regrettably, although all of the proteins that
bear these domains can potentially be identified by motif NOD1, in turn, is said to be capable of activating cas-
pase-9 (Inohara et al., 1999).searches, and dozens of proteins are now known to
exhibit them, only a restricted number of authentic inter- Unfortunately, there are no data bearing on the activa-
tion of NOD2 by the same pathway or an analogous one.actions are known to occur. Best characterized is the
Fas signaling pathway, which involves DD association At present, one might guess that NOD2 is ultimately
activated by a surface receptor and very likely by thebetween Fas and FADD, then DED association between
FADD and caspase-8 (Boldin et al., 1996; Muzio et al., TNF receptor (perhaps by way of RAIDD, perhaps by way
of RIP2), but the matter remains conjectural. Likewise,1996).
The first DD to be identified was that in the type I though not many cell lines have actually been examined,
the activation of caspases by NOD2 is a tantalizing pos-TNF receptor. It is capable of signaling by way of DD
associations involving TRADD (Hsu et al., 1996), RIP sibility, though not yet established. To date, it has been
found in transfection studies (Ogura et al., 2001b) that(Stanger et al., 1995), RAIDD (Thome et al., 1998), and
FADD (Chinnaiyan et al., 1996). Among these transduc- “overexpression of NOD2 by itself did not induce apo-
ptosis, but enhanced apoptosis induced by caspase-9ers, RIP is known to have two close homologs: RIP2
(McCarthy et al., 1998) (alternately known as RICK [Ino- expression.” And the LRR domain may indeed represent
the activation motif for an alternative activation pathway,hara et al., 1998] or CARDIAK [Thome et al., 1998]) and
RIP3 (Yu et al., 1999; Sun et al., 1999). All three members analogous to the Apaf-1 activation pathway.
The CARD domains of NOD1 and NOD2 (the latterof the RIP family have protein kinase domains, and all
are ultimately implicated in NF-B activation. protein has two closely apposed CARD domains) may
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be directly involved in activation of other caspases as proposed on phylogenetic grounds (Du et al., 2000).
But as already mentioned, not all such interactions arewell, though this also remains a guess. Among the 14
caspase family members known to exist in mammals, bound to lead to an apoptotic endpoint, and the
Pelle:Tube connection is one case in point. Though im-eight (caspase-1, -2, -4, -5, -9, -11, -12, and -13) have
CARD motifs. Two (caspase-8 [aka MACH or FLICE] portant in dorsoventral polarization of the Drosophila
embryo and also in the innate immune response of Dro-and -10), and also the inhibitory caspase homolog c-FLIP,
have DED motifs. Four (caspase-3, -6, -7, and -14) have sophila, no apoptosis is known to result from the binding
of Pelle to Tube. Likewise, the ultimate apoptotic poten-none of the interaction motifs characteristic of death
pathways. Hence, beyond caspase-9, there are many tial of Drosophila MyD88 has yet to be established.
“executioners” upon which CARD-bearing proteins (in-
cluding NOD2) might potentially impinge. On the other Why Are Defects of Apoptosis Linked
hand, not all CARD, DD, or DED interactions necessarily to Autoimmunity?
lead to the caspases at all. In the end, these domains The apoptotic apparatus of a cell does not exist in vacuo,
merely permit bimolecular interaction and are not bound but is necessarily subject to regulatory influences gov-
to elicit cell death a priori. erning which cells will die, how many cells will die, and
Although speculative, a case can be made for connec- when they will die. This is particularly true in the immune
tion between cell death receptors (notably the type I system, which undergoes intermittent cycles of expan-
TNF receptor) and the NOD proteins (Figure 2). If indeed sion and contraction as requisite clones are called into
mutations affecting death pathways are a common service to combat infection and then eliminated. Apo-
theme in Crohn’s disease, it might be noted that the ptotic pathways are now very much tied to the develop-
chromosomal location of caspase-6 corresponds ap- ment of peripheral tolerance (Wang and Lenardo, 1997).
proximately to another IBD susceptibility locus in the It may be reasoned that failure of an apoptotic pathway,
middle of chromosome 4q. But it must be pointed out caused by mutation of one of its components, might
that the association is, as usual, quite vague given the trigger countervailing proapoptotic responses, some of
limitations that are inherent in human gene mapping. which are associated with inflammation (Beutler and
Bazzoni, 1998).
The Possible Nexus between TLRs and NOD Proteins For example, a primary failure of apoptosis in Crohn’s
As already mentioned, the possibility that NOD2 acts as disease might cause reflexive overproduction of TNF.
a transducer of microbial signals cannot be dismissed, This could, in turn, help to eliminate cells. However, it
even if its role as a cytoplasmic receptor for microbial would also have deleterious proinflammatory effects,
inducers is not yet affirmed by strong genetic data. As- some of which would result from TNF’s concomitant
suming that a signal originates with a member of the ability to activate NF-B. Perhaps for this reason, block-
TLR family of proteins, could NOD2 become activated? ade of TNF activity has specific beneficial effects in
The TLR proteins do not have DD, CARD, or DED motifs. Crohn’s disease, as in rheumatoid arthritis. The exact
However, as indicated earlier, they do have a death nature of the signal leading to TNF production in these
pathway connection. MyD88, which is an essential sig- diseases remains unknown. If indeed it is reflexive, the
naling intermediate for at least some of the TLRs, has pathway that serves it could perhaps be inhibited (Fig-
two DD motifs. These domains are believed to serve the ure 3).
interaction of MyD88 with IRAK, a serine kinase that also
has DD motifs. But the possibility of other interactions Summary and Conclusions
remains open as well. One well-known consequence of Complex genetic disorders have begun to yield to se-
LPS stimulation in macrophages is the activation of ICE quential positional cloning initiatives. Both in humans
(caspase-1), a CARD-bearing member of the family. and in mice, given that multiple susceptibility loci can
Moreover, under certain conditions, LPS is known to be established, it is generally possible to dissect pheno-
cause macrophage apoptosis. In fact, it has long been types one gene at a time. The first step has been taken
known that RAW 264.7 macrophages, considered stan- in Crohn’s disease. But even simple genetic disorders
dard bearers of LPS responsiveness, are killed by LPS pose problems of interpretation once they are solved
(Raschke et al., 1978; Ralph and Nakoinz, 1977). Cas- by positional methods. How does huntingtin create its
pase-1 activation via MyD88 would require a DD:CARD phenotype? How do mutations of superoxide dismutase
adaptor protein (possibly RAIDD, though it has not been create amyotrophic lateral sclerosis? How do mutations
proven to actually fulfill this function). Whatever its iden- of NRAMP enhance susceptibility to mycobacterial in-
tity, the adaptor in question might equally comprise a fection? When numerous mutations are responsible for
link to the NOD proteins. a phenotype, the riddle is more challenging still. NOD2
In Drosophila, association between Pelle and Tube has become the eighth protein known to have strong
(which lie downstream from Toll in the dorsal pathway) is ties to cell death pathways and to autoimmunity. Muta-
mediated by a DD interaction (Xiao et al., 1999), perhaps tions of NOD2 are responsible for a discrete autoimmune
homologous to the IRAK:MyD88 interaction of mam- disease. But as to how they create the phenotype, much
mals. Drosophila MyD88 is not known to be required for remains to be learned.
either the developmental or antifungal responses of this
organism. MyD88 was never identified as a component
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